TIMI 38 and prasugrel

March 3, 2008- by Steven E. Greer, MD

One of the more important presentations at the upcoming American College of Cardiology meeting later this month will be a subset analysis of the stent thrombosis cases for Eli Lilly’s blockbuster hopeful prasugrel. Prasugrel would ideally compete for Plavix in the lucrative anticoagulation market. The FDA decision on prasugrel will also be one of the most important events this year in cardiology from a pharmaceutical perspective.

We interviewed the lead author for the TRITON-TIMI 38 study, Elliot Antman of Brigham and Women’s Hospital. The study was presented at the AHA last year and published in the NEJM.

This entry was posted in - Pharma, Cardiology. Bookmark the permalink.

Leave a Reply

Your email address will not be published.